disease 2,995 words KG: ent-dise-7f7b1bd3 2026-03-24
kind:diseasesection:diseasesstate:published
Contents

Aging-Related Tau Astrogliopathy (ARTAG)

Disease Info
PrevalenceFound in approximately 10-20% of cognitively normal elderly individuals
Full NameAging-Related Tau Astrogliopathy
AbbreviationARTAG
ClassificationNeurodegeneration / Tauopathy / Astrogliopathy
ICD-10 CodeG31.9 (Unspecified degenerative disease of nervous system)
AgePrimarily affects individuals over 70 years of age
Risk factorsAdvanced age is the primary risk factor
Gray matterSuperficial cortical layers (Layer 1-3), particularly in the frontal and temporal lobes
White matterPredominant white matter involvement
Subpial regionAlong the brain surface
Perivascular regionsAround small blood vessels
Common locationsFrontal cortex, temporal cortex, hippocampus
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (17)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62

Related Analyses (15)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived

Related Experiments (6)

Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40